CA AB1060

Requires health care service plan contracts and health insurance policies that provide prescription drug coverage and are issued, amended, delivered, or renewed on or after January 1, 2025, to cover prescription and nonprescription naloxone hydrochloride and all FDA-approved drugs for complete or partial reversal of opioid overdoses.

Prohibits cost-sharing requirements exceeding $10 per package of naloxone or FDA-approved opioid reversal drugs, with the $10 cap applying only to Tier 1 or Tier 2 formulary drugs or over-the-counter products at in-network pharmacies.

Requires insurers maintaining tiered drug formularies to include at least two FDA-approved opioid reversal drugs in Tiers 1 and 2 combined and mandates point-of-sale coverage for over-the-counter naloxone at in-network pharmacies.

Establishes naloxone hydrochloride and FDA-approved opioid reversal drugs as covered benefits under the Medi-Cal program.

All coverage requirements repeal on January 1, 2030; applies to health care service plans and health insurers but excludes Medi-Cal managed care plans to the extent services are excluded under their state contracts.